Trial · NCT03732807
Participant flow42
How many started, completed or left each group, period by period.
21 to 40 of 42
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Treatment Period (up to Week 24) | NOT COMPLETED | Placebo, Ritlecitinib (PF-06651600) 50 mg | 5 | |
| Treatment Extension (Week 25 up to 48) | STARTED | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | 113 | |
| Treatment Extension (Week 25 up to 48) | STARTED | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | 111 | |
| Treatment Extension (Week 25 up to 48) | STARTED | Ritlecitinib (PF-06651600) 50 mg | 108 | |
| Treatment Extension (Week 25 up to 48) | STARTED | Ritlecitinib (PF-06651600) 30 mg | 106 | |
| Treatment Extension (Week 25 up to 48) | STARTED | Ritlecitinib (PF-06651600) 10 mg | 49 | |
| Treatment Extension (Week 25 up to 48) | STARTED | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | 59 | |
| Treatment Extension (Week 25 up to 48) | STARTED | Placebo, Ritlecitinib (PF-06651600) 50 mg | 57 | |
| Treatment Extension (Week 25 up to 48) | COMPLETED | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | 107 | |
| Treatment Extension (Week 25 up to 48) | COMPLETED | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | 100 | |
| Treatment Extension (Week 25 up to 48) | COMPLETED | Ritlecitinib (PF-06651600) 50 mg | 103 | |
| Treatment Extension (Week 25 up to 48) | COMPLETED | Ritlecitinib (PF-06651600) 30 mg | 97 | |
| Treatment Extension (Week 25 up to 48) | COMPLETED | Ritlecitinib (PF-06651600) 10 mg | 44 | |
| Treatment Extension (Week 25 up to 48) | COMPLETED | Placebo, Ritlecitinib (PF-06651600) 200 mg Then 50 mg | 56 | |
| Treatment Extension (Week 25 up to 48) | COMPLETED | Placebo, Ritlecitinib (PF-06651600) 50 mg | 53 | |
| Treatment Extension (Week 25 up to 48) | NOT COMPLETED | Ritlecitinib (PF-06651600) 200 mg Then 50 mg | 6 | |
| Treatment Extension (Week 25 up to 48) | NOT COMPLETED | Ritlecitinib (PF-06651600) 200 mg Then 30 mg | 11 | |
| Treatment Extension (Week 25 up to 48) | NOT COMPLETED | Ritlecitinib (PF-06651600) 50 mg | 5 | |
| Treatment Extension (Week 25 up to 48) | NOT COMPLETED | Ritlecitinib (PF-06651600) 30 mg | 9 | |
| Treatment Extension (Week 25 up to 48) | NOT COMPLETED | Ritlecitinib (PF-06651600) 10 mg | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03732807/flow?page=2